Department of Cardiology, Santa Maria della Misericordia Hospital, Via Tre Martiri 140, 45100 Rovigo, Italy.
Department of Cardiology, University Hospital, via Aldo Moro, n 8, 44124 Ferrara, Italy.
Europace. 2023 May 19;25(5). doi: 10.1093/europace/euad082.
In patients with prolonged atrioventricular (AV) conduction and pacemaker (PM) indication due to sinus node disease (SND) or intermittent AV-block who do not need continuous ventricular pacing (VP), it may be difficult to determine which strategy to adopt. Currently, the standard of care is to minimize unnecessary VP by specific VP avoidance (VPA) algorithms. The superiority of this strategy over standard DDD or DDD rate-responsive (DDD/DDDR) in improving clinical outcomes is controversial, probably owing to the prolongation of the atrialventricular conduction (PR interval) caused by the algorithms. Conduction system pacing (CSP) may offer the most physiological-VP approach, providing appropriate AV conduction and preventing pacing-induced dyssynchrony.
PhysioVP-AF is a prospective, controlled, randomized, single-blind trial designed to determine whether atrial-synchronized conduction system pacing (DDD-CSP) is superior to standard DDD-VPA pacing in terms of 3-year reduction of persistent-AF occurrence. Cardiovascular hospitalization, quality-of-life, and safety will be evaluated. Patients with indication for permanent DDD pacing for SND or intermittent AV-block and prolonged AV conduction (PR interval > 180 ms) will be randomized (1:1 ratio) to DDD-VPA (VPA-algorithms ON, septal/apex position) or to DDD-CSP (His bundle or left bundle branch area pacing, AV-delay setting to control PR interval, VPA-algorithms OFF). Approximately 400 patients will be randomized in 24 months in 13 Italian centres.
The PhysioVP-AF study will provide an essential contribution to patient management with prolonged AV conduction and PM indication for sinus nodal disease or paroxysmal 2nd-degree AV-block by determining whether CSP combined with a controlled PR interval is superior to standard management that minimizes unnecessary VP in terms of reducing clinical outcomes.
对于因窦房结疾病(SND)或间歇性房室传导阻滞而需要房室(AV)传导延长和起搏器(PM)适应证且不需要连续心室起搏(VP)的患者,可能难以确定采用哪种策略。目前,标准治疗方法是通过特定的避免不必要的 VP(VPA)算法来最小化不必要的 VP。该策略在改善临床结局方面优于标准的双腔(DDD)或双腔频率适应性(DDD/DDDR)的优势存在争议,这可能是由于算法导致 AV 传导延长(PR 间期)所致。心脏传导系统起搏(CSP)可能提供最生理的 VP 方法,提供适当的 AV 传导并防止起搏引起的不同步。
PhysioVP-AF 是一项前瞻性、对照、随机、单盲试验,旨在确定心房同步传导系统起搏(DDD-CSP)是否优于标准的 DDD-VPA 起搏,以降低持续性房颤发生的 3 年发生率。将评估心血管住院、生活质量和安全性。对于因 SND 或间歇性 AV 阻滞且 AV 传导延长(PR 间期>180ms)而需要永久性 DDD 起搏的患者,将按照 1:1 的比例随机(1:1 比例)分为 DDD-VPA(VPA 算法开启,间隔部/心尖部位置)或 DDD-CSP(希氏束或左束支区域起搏,AV 延迟设置以控制 PR 间期,VPA 算法关闭)。在 24 个月内,预计将在意大利的 13 个中心招募大约 400 名患者。
PhysioVP-AF 研究将通过确定 CSP 联合控制 PR 间期是否优于最小化不必要的 VP 以降低临床结局的标准治疗方法,为延长 AV 传导和 PM 适应证因窦房结疾病或阵发性 2 度房室传导阻滞的患者管理提供重要贡献。